A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
This is a study designed to evaluate the efficacy and safety of oral YY-20394 in patients with R/R follicular non-Hodgkin's lymphoma who have failed at least two prior systemic therapies.
Lymphoma, Follicular
DRUG: YY-20394
Overall response rate, ORR, Overall response rate (ORRProportion of patients whose tumor volume reduces to a predetermined value and can maintain the minimum time limit-) assessed by an Independent Review Committee (IRC)., Throughout the study for approximately 2 years
Overall response rate (ORR), Overall response rate (ORR-Proportion of patients whose tumor volume reduces to a predetermined value and can maintain the minimum time limit) assessed by reseachers., Throughout the study for approximately 2 years|Progression free survival, PFS, PFS, defined as the time from the first dose of study treatment to first documented disease progression or death due to any cause, whichever occurs first., Throughout the study for approximately 2 years|Overall survival, OS, The time from randomization to death for any reason., Throughout the study for approximately 2 years|Disease control rate, DCR, The percentage of cases with remission (PR+CR)and stable lesions(SD) after treatment in the number of evaluable cases., Throughout the study for approximately 2 years
The study will be conducted in China to provide safety and efficacy data from this region. A Safety Run-in will be conducted to confirm the safety of the recommended Phase 2 dose (RP2D), 80 mg once daily, in a Asian population. PK samplings at Cycle 1, Day 1 will be taken.